If there was one lesson from the bi-polar year of dealmaking in 2000 it was that dealmaking leverage lies with those with the power to either keep and profit from the status quo or remake it. Investors' understanding of Big Pharma's growth troubles encouraged near bio-hysteria among investors for genomics start-ups-but the interest had little staying power, particularly given the relative paucity of drug company discovery alliances. Much better performances came from smaller companies with later-stage products, in-licensing prices for which have now reached almost unsupportable levels. Diagnostics start-ups have likewise been hot as investors recognize that the nearest-term potential of genomics and proteomics technologies lies in disease markers as well as markers for drug function. But medical device dealmaking has been quiet. Start-ups have by and large been unable to show significant growth or the ability to substantially reshape medical device segments--leading to both quiescent acquisition markets and apathetic investors.
by Roger Longman
There is something almost bi-polar about the medical industry of 2000: hysteria and depression following each other like the days of the week. The veneer covering the wax-and-bubble-gum foundation of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
